Due to what is seemingly a successful comeback, you can expect Intercept Pharmaceuticals to potentially deliver several-fold returns. Obeticholic acid's revenue for PBC alone is nearly enough to bank ...
Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
After last Friday’s unfavorable AdCom meeting, Intercept’s NASH candidate now appears dead on arrival. Some analysts have suggested that Intercept's valuation will be buttressed by their PBC franchise ...
Intercept Pharmaceuticals' Q2 earnings reveal 17% growth in revenue and focus on Ocaliva for treating PBC, discontinuing NASH development. Despite strong revenue growth and promising Ocaliva expansion ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for ...
Intercept Pharmaceuticals markets and sells Ocaliva to patients with primary biliary cholangitis. Sales grew >10% in 2022 and are forecast to grow ~14% in 2023, to ~$325m, but the much larger market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback